4 - IGC Pharma, Inc. (0001326205) (Issuer)

5 - IGC Pharma, Inc. (0001326205) (Issuer)

5 - IGC Pharma, Inc. (0001326205) (Issuer)

5 - IGC Pharma, Inc. (0001326205) (Issuer)

5 - IGC Pharma, Inc. (0001326205) (Issuer)

4 - IGC Pharma, Inc. (0001326205) (Issuer)

4 - IGC Pharma, Inc. (0001326205) (Issuer)

4 - IGC Pharma, Inc. (0001326205) (Issuer)

3 - IGC Pharma, Inc. (0001326205) (Issuer)

4 - IGC Pharma, Inc. (0001326205) (Issuer)

4 - IGC Pharma, Inc. (0001326205) (Issuer)

8-K - IGC Pharma, Inc. (0001326205) (Filer)

424B5 - IGC Pharma, Inc. (0001326205) (Filer)

DEFA14A - IGC Pharma, Inc. (0001326205) (Filer)

DEF 14A - IGC Pharma, Inc. (0001326205) (Filer)

10-Q - IGC Pharma, Inc. (0001326205) (Filer)

PRE 14A - IGC Pharma, Inc. (0001326205) (Filer)

EFFECT - IGC Pharma, Inc. (0001326205) (Filer)

S-3 - IGC Pharma, Inc. (0001326205) (Filer)

10-K - IGC Pharma, Inc. (0001326205) (Filer)

8-K - IGC Pharma, Inc. (0001326205) (Filer)

POTOMAC, MD / ACCESS Newswire / January 21, 2025 / IGC Pharma, Inc. (NYSE:IGC) ("IGC Pharma" or the "Company") is pleased to announce the appointment of Terry McAuliffe, the 72nd Governor of Virginia, as a strategic advisor. Governor McAuliffe's extensive leadership experience across public and private sectors will play a pivotal role in advancing IGC Pharma's mission to redefine Alzheimer's care and position the Company for growth in the biotechnology and pharmaceutical industries. As strategic advisor, Governor McAuliffe will focus on refining IGC Pharma's growth strategies, driving business development initiatives, and fostering partnerships with leading pharmaceutical and healthcare o

POTOMAC, MD / ACCESSWIRE / January 13, 2025 / IGC Pharma, Inc (NYSE:IGC) ("IGC" or the "Company"), today announced that CEO Ram Mukunda and CCO Claudia Grimaldi will be participating in a fireside chat hosted by Ascendiant Capital Markets on Thursday, January 23, 2025, at 1:00 pm ET. During the session, IGC Pharma's management will provide insights into the Company's recent progress, including advancements in its Alzheimer's pipeline, strategic expansion into metabolic disorders, and the integration of artificial intelligence in drug discovery. They will also discuss key upcoming milestones, including new clinical trial launches, preclinical developments, and efforts to broaden the Compa

Innovative use of geofencing technology boosts enrollment at select sites POTOMAC, MD / ACCESSWIRE / January 8, 2025 / IGC Pharma, Inc. (NYSE:IGC) ("IGC Pharma" or the "Company") announced today that its ongoing Phase 2 trial for agitation in Alzheimer's disease has been officially named CALMA (Calming Agitation in Alzheimer's).The trial's new identity reflects its mission to address agitation, a syndrome affecting up to 76% of the 55 million Alzheimer's patients worldwide that also adversely impacts the quality of life for both patients and their caregivers.To accelerate enrollment across all clinical sites, IGC Pharma has implemented an innovative recruitment campaign leveraging geofencing

POTOMAC, MD / ACCESSWIRE / December 19, 2024 / IGC Pharma, Inc. ("IGC" or the "Company") (NYSE:IGC) today announced that the Company's management team will participate in BIO Partnering @ JPM, scheduled alongside the J.P. Morgan 43rd Annual Healthcare Conference 2025. Management will be available for in-person and virtual meetings.Details of the events are as follows:Event: BIO Partnering @ JPMDate: January 13 - 16, 2025Registration: https://www.bio.org/events/bio-partnering-jpm/registrationThe IGC management team will conduct one-on-one meetings with registered investors and pharmaceutical companies, showcasing the Company's business strategy, recent partnerships and achievements, and antic

New trials to evaluate IGC-AD1's potential impact on amyloid plaque, tau tangles, and cognitive decline in Alzheimer's diseaseExpanded research positions IGC-AD1 as a potential treatment targeting the underlying disease pathology of Alzheimer's POTOMAC, MARYLAND / ACCESSWIRE / December 2, 2024 / IGC Pharma, Inc. (NYSE:IGC) ("IGC Pharma" or the "Company") announced today an expansion of its clinical research program for IGC-AD1, an investigational treatment for Alzheimer's disease. Building on Phase 2 interim results demonstrating reductions in agitation and cognitive improvement, the Company is initiating new trials to evaluate IGC-AD1's potential as a disease-modifying therapy.The expanded

- Interim results indicate cognitive improvement in the active treatment group compared to placebo - No serious adverse events or deaths reported in the trial IGC Pharma, Inc. (NYSE:IGC) ("IGC Pharma" or the "Company") today announced additional interim data from its ongoing Phase 2 clinical trial evaluating IGC-AD1. The trial focuses on agitation in Alzheimer's as its primary outcome, with cognition assessed as an exploratory outcome. Interim data analysis reveals cognitive improvements in the active treatment group versus the placebo group, marking a meaningful step toward developing a therapy that may influence underlying disease progression. These findings align with previously an

POTOMAC, MD / ACCESSWIRE / November 14, 2024 / IGC Pharma, Inc. ("IGC" or the "Company") (NYSE:IGC) today announced its financial results and strategic advancements for the second fiscal quarter of 2025 ended September30, 2024. The quarter was marked by significant progress in the Company's pipeline, particularly in the development of potential treatments for Alzheimer's and other neurological and metabolic disorders. IGC Pharma, Inc. Q2 FY2025 Company's HighlightsCrossing the Blood-Brain Barrier with TGR-63: July 9, 2024 - Preclinical analyses for TGR-63 demonstrated this compound's ability to cross the blood-brain barrier with a favorable safety profile, positioning it for further therap

POTOMAC, MD / ACCESSWIRE / November 6, 2024 / IGC Pharma, Inc. (NYSE:IGC) ("IGC Pharma" or the "Company") is pleased to announce the publication of a new interview with CEO Ram Mukunda, now available as part of the IMS Spotlight Series.In the interview, Ram Mukunda discusses IGC's strategic expansion into metabolic and neurological markets, specifically addressing the potential of GLP-1 agonists in both Alzheimer's and weight loss therapies. Mukunda also provides updates on IGC Pharma's lead candidate, IGC-AD1, which is currently in Phase 2 trials for treating agitation in Alzheimer's dementia and is progressing toward additional trials to explore its potential as a disease-modifying treatme

- Company Expands Phase 2 trial to Canada -POTOMAC, MD / ACCESSWIRE / October 17, 2024 / IGC Pharma, Inc (NYSE:IGC) ("IGC" or the "Company"), today announced enrollment of patients at the Baycrest Academy for Research and Education in Toronto, Ontario, Canada, as part of the Company's ongoing Phase 2 trial investigating IGC-AD1 as a treatment for agitation in Alzheimer's dementia.Agitation affects between 40-80% of Alzheimer's patients and is a major driver of long-term hospitalization, increased mortality, and higher use of medication.IGC-AD1 is a partial CB1 receptor agonist with anti-neuroinflammatory properties and acts as an inflammasome inhibitor, addressing key pathways involved in th

POTOMAC, MD / ACCESSWIRE / October 3, 2024 / IGC Pharma, Inc. (NYSE:IGC) proudly announces that it won 2 awards in the PREPARE Challenge (Pioneering Research for Early Prediction of Alzheimer's and Related Dementias EUREKA Challenge), with its entry of the Mexican Health and Aging Study ("MHAS") database. IGC Pharma, Inc. The PREPARE Challenge is sponsored by the National Institute on Aging ("NIA"), an institute of the National Institutes of Health ("NIH"). The competition aims to accelerate the development of more accurate, innovative, and representative tools for Alzheimer's and related dementias. The Disproportionate Impact prize recognizes the submission with the most potential to

POTOMAC, MD / ACCESS Newswire / January 21, 2025 / IGC Pharma, Inc. (NYSE:IGC) ("IGC Pharma" or the "Company") is pleased to announce the appointment of Terry McAuliffe, the 72nd Governor of Virginia, as a strategic advisor. Governor McAuliffe's extensive leadership experience across public and private sectors will play a pivotal role in advancing IGC Pharma's mission to redefine Alzheimer's care and position the Company for growth in the biotechnology and pharmaceutical industries. As strategic advisor, Governor McAuliffe will focus on refining IGC Pharma's growth strategies, driving business development initiatives, and fostering partnerships with leading pharmaceutical and healthcare o

IGC Pharma, Inc. ("IGC" or the "Company") (NYSE:IGC) announces that during its Annual Meeting of Stockholders scheduled for and convened on August 23, 2023 (the "Annual Meeting"), all proposals as disclosed on the Definitive Proxy Statement on Schedule 14A filed with the SEC on July 8, 2024, were passed by the requisite vote of the stockholders. Only stockholders of record on the record date of June 28, 2024, were entitled to and requested to vote at the Annual Meeting. At the Annual Meeting, all of the following proposals were approved by the requisite vote of the stockholders: (i) the election of Mr. Richard Prins and Mr. Terry Lierman to the Company's board of directors to serve as Cla

IGC Pharma, Inc. ("IGC Pharma," "IGC," or the "Company") (NYSE:IGC) today announced that it has appointed Terry Lierman as an independent director to its board of directors. Mr. Lierman is currently Co-Chair of the Board of Advisors at the Institute of Human Virology (IHV), a center in the U.S. focused on accelerating the discovery of diagnostics and therapeutics for deadly viral and immune disorders and a member of the Board of Visitors at the La Follette School of Public Affairs at the University of Wisconsin, his alma mater. Terry founded the Children's Research Institute, one of America's top children's research programs, the Pancreatic Cancer Action Network (PanCAN), and the National

India Globalization Capital, Inc. (NYSE:IGC) announces that the Board has appointed Ms. Claudia Grimaldi as a non-independent Director, effective March 23, 2022. IGC now has 5 directors including a majority who are independent. Ms. Grimaldi has been with IGC for almost 12 years with increasing responsibilities including managing SEC and NYSE filings, regulatory compliance, and disclosures. She is currently Vice President, Principal Finance Officer, and Chief Compliance Officer. She is also the Managing Director of Hamsa Biochem SAS, our subsidiary in Colombia, as well as a director of our subsidiary in India. Ms. Grimaldi stated: "I hope to bring diversity of thought and perspective to th

India Globalization Capital, Inc. (NYSE:IGC) is excited to announce that the Board has appointed former Congressman Jim Moran ("Congressman Moran") as an independent Director. IGC is delighted to welcome Congressman Moran to its Board of Directors. Congressman Moran served Virginia's 8th Congressional District for 24 years, where he was known as a "Problem Solver." Throughout his tenure, he demonstrated bipartisan leadership and worked across the aisle to find common ground to resolve complex issues. He served on the Appropriation, Banking and Finance and Budget committees. He played a leadership role in the areas of defense, health, and the environment. During his 24 years in Congress, C

POTOMAC, Md.--(BUSINESS WIRE)--India Globalization Capital, Inc. (NYSE AMERICAN: IGC) announces that during its Annual Meeting of Shareholders scheduled for, and convened on January 11, 2021, voting on all matters as disclosed on the Definitive Proxy on Form 14A filed with the SEC on December 8, 2020 were passed. Only stockholders of record on the record date of November 20, 2020, were entitled to and were being requested to vote. At the Annual Meeting, the following proposals were approved: (i) the election of John E. Lynch to the Company’s Board of Directors; (ii) the proposal to ratify Manohar Chowdhry & Associates (“MCA”) as the Company’s independent registered public account

SC 13D/A - IGC Pharma, Inc. (0001326205) (Subject)

SC 13D - IGC Pharma, Inc. (0001326205) (Subject)

POTOMAC, MD / ACCESSWIRE / November 14, 2024 / IGC Pharma, Inc. ("IGC" or the "Company") (NYSE:IGC) today announced its financial results and strategic advancements for the second fiscal quarter of 2025 ended September30, 2024. The quarter was marked by significant progress in the Company's pipeline, particularly in the development of potential treatments for Alzheimer's and other neurological and metabolic disorders. IGC Pharma, Inc. Q2 FY2025 Company's HighlightsCrossing the Blood-Brain Barrier with TGR-63: July 9, 2024 - Preclinical analyses for TGR-63 demonstrated this compound's ability to cross the blood-brain barrier with a favorable safety profile, positioning it for further therap

IGC Pharma, Inc. ("IGC" or the "Company") (NYSE:IGC) today announced its financial results for the first fiscal quarter of 2025 ended June 30, 2024. Q1 FY2025 Company's Highlights On April 9, 2024, the Company welcomed Pablo Arbelaez, Ph.D., a renowned AI expert and researcher, to support the development of the Phase 2 clinical trial of IGC-AD1, the lead therapeutic candidate addressing agitation in Alzheimer's disease. On April 16, 2024, the Company announced that interim data from its Phase 2 clinical trial demonstrates a clinically significant reduction, approaching statistical significance, in agitation in Alzheimer's at week two compared to placebo. On May 28, 2024, the Comp

IGC Pharma, Inc. ("IGC" or the "Company") (NYSE:IGC), a clinical-stage pharmaceutical company, has announced its financial results for the fiscal year ended March 31, 2024 ("Fiscal 2024"). Full Fiscal Year Highlights In March 2024, the Company announced positive interim results from its ongoing Phase 2 trial for IGC-AD1. The interim data have shown promising results in reducing Alzheimer's agitation, which is a major challenge for patients and their caregivers alike. This development marks a significant step forward in the fight against Alzheimer's and brings hope to millions of people affected by this devastating disease. In January 2024, the Company announced details about its dru

IGC Pharma, Inc. ("IGC" or the "Company") (NYSE:IGC) today announced its financial results for the third fiscal quarter of 2024 ended December 31, 2023 (Q3 FY 2024). Q3 FY2024 Highlights On October 18, 2023, the European Patent Office ("EPO") issued a patent (#3193862) to the Company titled "Cannabinoid Composition and Method for Treating Pain". The patent introduces a method for treating pain in humans. Utilizing a cream base infused with a unique blend of cannabinoids, including THC and CBD, alongside other compounds, this revolutionary cream, or gel is designed for transdermal absorption. On October 25, 2023, the Divisional Direction of Patents, Mexico, issued a patent (MX/a/2020

IGC-ADI addressing agitation in dementia due to Alzheimer's progresses in Phase 2 Trial Company focuses on advancing the development of an expanded IP portfolio targeting Alzheimer's IGC Pharma, Inc. ("IGC" or the "Company") (NYSE:IGC) today announced its financial results for the second fiscal quarter of 2024 ended September 30, 2023 (Q2 FY2024). Q2 FY2024 Highlights Revenue in Q2 FY2024 increased 44% to approximately $291,000 compared to the same quarter in FY2023 at roughly $202,000. In the first six months of FY2024, revenue doubled to about $846,000 from about $414,000 compared to the prior year's six-month period. IGC's revenue was primarily generated from our over-the-cou

IGC Pharma, Inc. ("IGC" or the "Company") (NYSE:IGC) today announced its financial results for the quarter ended June 30, 2023, which is the first quarter of the Company's 2024 fiscal year. First Fiscal Quarter 2024 Highlights Net revenue increased 161% to approximately $555 thousand in the three months ended June 30, 2023, compared to $212 thousand in the prior year period, driven primarily by the sale of formulations based on the Holief brand natural products targeting women with premenstrual syndrome ("PMS"), period pain, and sleep disorders. Throughout the quarter, IGC Pharma maintained substantial momentum in the development of a Phase 3 manufacturing facility located on the We

IGC Pharma, Inc. ("IGC" or the "Company") (NYSE:IGC), a clinical-stage pharmaceutical company, today announced its financial results for the fiscal year ended March 31, 2023 ("Fiscal 2023"). Full Fiscal Year Highlights and Events Subsequent Thereto On July 7, 2023, the Company announced a $12 million revolving line of credit from the Hong Kong Branch of O-Bank Co. Ltd. ("O-Bank" or the "Bank"). This funding will support the working capital needs of the Company, primarily related to Alzheimer's research. On July 6, 2023, the Company announced a $3 million private placement of its common stock. IGC received strategic investments from four investment funds managed by Bradbury Asset Ma

POTOMAC, Md., Feb. 14, 2023 (GLOBE NEWSWIRE) -- via InvestorWire -- India Globalization Capital, Inc. (dba IGC, Inc.) (NYSE:IGC) ("IGC" or the "Company") today reported its third fiscal quarter 2023 financial results. Third Fiscal Quarter 2023 Highlights: The Company expanded the number of sites participating in its Phase 2 clinical trial on IGC-AD1 for agitation in dementia from Alzheimer's disease to a total of four – three in the U. S. and one in Canada. The Company is encouraged by the patient enrollment and interest from many of the leading research centers and has decided to increase the number of trial sites to between 10 and 12 from the originally planned

Company To Host Conference Call on Friday, December 2 at 11 a.m. ET India Globalization Capital, Inc. (NYSE:IGC) ("IGC" or the "Company"), announced that it has begun "A Phase 2, Multi-Center, Double-Blind, Randomized, Placebo-Controlled, Trial of the Safety and Efficacy of IGC-AD1 on Agitation in Participants with Dementia due to Alzheimer's Disease". The Company has commenced the Phase 2 study at two U.S. sites with plans to add between three to five additional sites in the United States, Canada, and possibly South America to increase population diversity, promoting both the inclusion of underrepresented populations and helping the Company to better understand the impact of IGC-AD1 on t

India Globalization Capital, Inc. (NYSE:IGC) ("IGC" or the "Company") today reported its second fiscal quarter 2023 financial results. Second Fiscal Quarter 2023 Highlights: IGC-AD1 and TGR-63, both small molecules, have shown potential to suppress or ameliorate a key protein in Alzheimer's cell lines responsible for Aβ plaques, a key hallmark of Alzheimer's disease. The Company currently has two main investigational drug assets in various stages of development: IGC-AD1: The Company's therapeutic candidate is entering Phase 2 trials for treating agitation in dementia from Alzheimer's disease. TGR-63: An enzyme inhibitor shown in preclinical trials to reduce neurotoxicity in Alzheimer